S&P Global Ratings’ ESG Evaluation of 87 reflects our assessment of Sanofi’s innovation capacity, which we think will help drive the industry forward, as well as the concrete steps it has already taken in implementing its strategy. The group’s Play to Win strategy sets a framework for growth, mainly through research and development (R&D) and operating efficiency improvements.